Flu Vaccine Market Overview | Canada News Media
Connect with us

Health

Flu Vaccine Market Overview

Published

 on

Flu Vaccine

AMA Research added a comprehensive research document of 200+ pages on ‘Flu Vaccine’ market  with detailed insights on growth factors and strategies. The study segments key regions that includes North America, Europe, Asia-Pacific with country level break-up and provide volume* and value related cross segmented information by each country. Some of the important players from a wide list of coverage used under bottom-up approach are CSL Limited (Australia),GlaxoSmithKline plc (United Kingdom),Sanofi Pasteur (France),Mylan N.V (United States),AstraZeneca PLC (United Kingdom),Pfizer Inc. (United States),Johnson & Johnson (United States),Sinovac Biotec Ltd. (China),Novartis AG (Switzerland),MedImmune (United States),Solvay (Belgium),Sequirus Limited (United Kingdom)

Request a sample report @ https://www.advancemarketanalytics.com/sample-report/13471-global-flu-vaccine-market-1

According to the World Health Organization (WHO), 2018, Influenza cases related to hospitalization ranges in 3-5 million cases for severe illness, whereas Deaths related to Influenza are about 290,000 to 650,000. The unhealthy food habits of people coupled with seasonal outbreaks have accelerated the growth of Pandemic Vaccine production with the novel Vaccine Technology across Emerging countries. The influenza virus, also called flu, is a contagious respiratory illness caused by Influenza viruses that infect the nose, throat, and sometimes the lungs. It can cause mild to severe illness, and at times can lead to death. A Flu vaccine is a combination of three Influenza viruses namely, Influenza type A with H3N2 virus strain, Influenza type A with H1N1 virus strain and Influenza type B virus strain. Vaccine available in the market such as Quadrivalent Influenza Vaccine (split virion, inactivated) is indicated for active immunization of adults and children from 6 months of age and older for the prevention of influenza disease caused by the two Influenza A virus subtypes and the two Influenza B virus types contained in the vaccine.

Market Segmentation

by  Type (Whole Virus Vaccines, Split Virus Vaccines, Subunit Vaccines, Live Attenuated Virus Vaccines), Application (For Children (6 months to 3 years), For Adults and Children over 3 years), Vaccine (Trivalent, Quadrivalent)

Check for Discount @ https://www.advancemarketanalytics.com/request-discount/13471-global-flu-vaccine-market-1

Highlights of Influencing Trends: High Demand for the Quadrivalent Vaccine due to inexpensive nature & also the vaccine got approval from the Food & Drug Administration in 2017.

Market Growth Drivers: The Emergent Government Policies and Innovations in Influenza Vaccine

Increasing Disease Awareness on Influenza Caused By the Threat of A Pandemic Influenza Outbreak

Wide Vaccination Coverage for Influenza Virus

The aging population and increasing prevalence of chronic diseases

Restraints: Varying demand & Limited Production Capacity

High Level of Required Investment

Strict Regulations is presenting barriers to the New Entrants of The Market.

Opportunities: Various companies have their on-going activities for newer technological development  Novel Influenza vaccine helping the market to revolutionize.

Challenges: Trivalent vaccines did not cover the entire Influenza type B virus.

View Detailed Table of Content @ https://www.advancemarketanalytics.com/reports/13471-global-flu-vaccine-market-1

Country level Break-up includes:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in depth analysis of the major vendor/key players in the market.

Furthermore, the years considered for the study are as follows:

Historical year – 2013-2017

Base year – 2018

Forecast period** – 2019 to 2025 [** unless otherwise stated]

**Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product services of key players.

Important Features that are under offering & key highlights of the report:

– Market Data Segmentation with production, consumption, revenue (million USD), and Price Analysis

– Detailed overview of Flu Vaccine market

– Changing market dynamics of the industry

– In-depth market segmentation by Type, Application etc

– Historical, current and projected market size in terms of volume and value

– Recent industry trends and developments

– Competitive landscape of Flu Vaccine market

– Strategies of key players and product offerings

– Potential and niche segments/regions exhibiting promising growth

– A neutral perspective towards Flu Vaccine market performance

– Must-have information for market players to sustain and enhance their market footprint

* Customized Section/Chapter wise Reports or Regional or Country wise Chapters are also available.

On Special Request we do offer a dedicated and focus report on regional or by country level scope.

Get full copy of United States Flu Vaccine Market Study @ ——— USD 2000

And, Southeast Asia Flu Vaccine Market Study @ ——— USD 2500

Table of Contents

Global Flu Vaccine Market Research Report

Chapter 1 Global Flu Vaccine Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Productions, Revenue (Value) by Region

Chapter 5 Global Supplies (Production), Consumption, Export, Import by Regions

Chapter 6 Global Productions, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Flu Vaccine Market Forecast

Key questions answered

  • Who are the Leading key players and what are their Key Business plans in the Global Flu Vaccine market?
  • What are the key concerns of the five forces analysis of the Global Flu Vaccine market?
  • What are different prospects and threats faced by the dealers in the Global Flu Vaccine market?
  • What are the strengths and weaknesses of the key vendors?

Buy this report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=13471

Source link

Continue Reading

Health

Canada to donate up to 200,000 vaccine doses to combat mpox outbreaks in Africa

Published

 on

 

The Canadian government says it will donate up to 200,000 vaccine doses to fight the mpox outbreak in Congo and other African countries.

It says the donated doses of Imvamune will come from Canada’s existing supply and will not affect the country’s preparedness for mpox cases in this country.

Minister of Health Mark Holland says the donation “will help to protect those in the most affected regions of Africa and will help prevent further spread of the virus.”

Dr. Madhukar Pai, Canada research chair in epidemiology and global health, says although the donation is welcome, it is a very small portion of the estimated 10 million vaccine doses needed to control the outbreak.

Vaccine donations from wealthier countries have only recently started arriving in Africa, almost a month after the World Health Organization declared the mpox outbreak a public health emergency of international concern.

A few days after the declaration in August, Global Affairs Canada announced a contribution of $1 million for mpox surveillance, diagnostic tools, research and community awareness in Africa.

On Thursday, the Africa Centres for Disease Control and Prevention said mpox is still on the rise and that testing rates are “insufficient” across the continent.

Jason Kindrachuk, Canada research chair in emerging viruses at the University of Manitoba, said donating vaccines, in addition to supporting surveillance and diagnostic tests, is “massively important.”

But Kindrachuk, who has worked on the ground in Congo during the epidemic, also said that the international response to the mpox outbreak is “better late than never (but) better never late.”

“It would have been fantastic for us globally to not be in this position by having provided doses a much, much longer time prior than when we are,” he said, noting that the outbreak of clade I mpox in Congo started in early 2023.

Clade II mpox, endemic in regions of West Africa, came to the world’s attention even earlier — in 2022 — as that strain of virus spread to other countries, including Canada.

Two doses are recommended for mpox vaccination, so the donation may only benefit 100,000 people, Pai said.

Pai questioned whether Canada is contributing enough, as the federal government hasn’t said what percentage of its mpox vaccine stockpile it is donating.

“Small donations are simply not going to help end this crisis. We need to show greater solidarity and support,” he said in an email.

“That is the biggest lesson from the COVID-19 pandemic — our collective safety is tied with that of other nations.”

This report by The Canadian Press was first published Sept. 13, 2024.

Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

How many Nova Scotians are on the doctor wait-list? Number hit 160,000 in June

Published

 on

 

HALIFAX – The Nova Scotia government says it could be months before it reveals how many people are on the wait-list for a family doctor.

The head of the province’s health authority told reporters Wednesday that the government won’t release updated data until the 160,000 people who were on the wait-list in June are contacted to verify whether they still need primary care.

Karen Oldfield said Nova Scotia Health is working on validating the primary care wait-list data before posting new numbers, and that work may take a matter of months. The most recent public wait-list figures are from June 1, when 160,234 people, or about 16 per cent of the population, were on it.

“It’s going to take time to make 160,000 calls,” Oldfield said. “We are not talking weeks, we are talking months.”

The interim CEO and president of Nova Scotia Health said people on the list are being asked where they live, whether they still need a family doctor, and to give an update on their health.

A spokesperson with the province’s Health Department says the government and its health authority are “working hard” to turn the wait-list registry into a useful tool, adding that the data will be shared once it is validated.

Nova Scotia’s NDP are calling on Premier Tim Houston to immediately release statistics on how many people are looking for a family doctor. On Tuesday, the NDP introduced a bill that would require the health minister to make the number public every month.

“It is unacceptable for the list to be more than three months out of date,” NDP Leader Claudia Chender said Tuesday.

Chender said releasing this data regularly is vital so Nova Scotians can track the government’s progress on its main 2021 campaign promise: fixing health care.

The number of people in need of a family doctor has more than doubled between the 2021 summer election campaign and June 2024. Since September 2021 about 300 doctors have been added to the provincial health system, the Health Department said.

“We’ll know if Tim Houston is keeping his 2021 election promise to fix health care when Nova Scotians are attached to primary care,” Chender said.

This report by The Canadian Press was first published Sept. 11, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

Newfoundland and Labrador monitoring rise in whooping cough cases: medical officer

Published

 on

 

ST. JOHN’S, N.L. – Newfoundland and Labrador‘s chief medical officer is monitoring the rise of whooping cough infections across the province as cases of the highly contagious disease continue to grow across Canada.

Dr. Janice Fitzgerald says that so far this year, the province has recorded 230 confirmed cases of the vaccine-preventable respiratory tract infection, also known as pertussis.

Late last month, Quebec reported more than 11,000 cases during the same time period, while Ontario counted 470 cases, well above the five-year average of 98. In Quebec, the majority of patients are between the ages of 10 and 14.

Meanwhile, New Brunswick has declared a whooping cough outbreak across the province. A total of 141 cases were reported by last month, exceeding the five-year average of 34.

The disease can lead to severe complications among vulnerable populations including infants, who are at the highest risk of suffering from complications like pneumonia and seizures. Symptoms may start with a runny nose, mild fever and cough, then progress to severe coughing accompanied by a distinctive “whooping” sound during inhalation.

“The public, especially pregnant people and those in close contact with infants, are encouraged to be aware of symptoms related to pertussis and to ensure vaccinations are up to date,” Newfoundland and Labrador’s Health Department said in a statement.

Whooping cough can be treated with antibiotics, but vaccination is the most effective way to control the spread of the disease. As a result, the province has expanded immunization efforts this school year. While booster doses are already offered in Grade 9, the vaccine is now being offered to Grade 8 students as well.

Public health officials say whooping cough is a cyclical disease that increases every two to five or six years.

Meanwhile, New Brunswick’s acting chief medical officer of health expects the current case count to get worse before tapering off.

A rise in whooping cough cases has also been reported in the United States and elsewhere. The Pan American Health Organization issued an alert in July encouraging countries to ramp up their surveillance and vaccination coverage.

This report by The Canadian Press was first published Sept. 10, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version